Secular trends in opportunistic infections, cancers and mortality in patients with AIDS during the era of modern combination antiretroviral therapy by Sezgin, Efe et al.
Secular trends in opportunistic infections, cancers and
mortality in patients with AIDS during the era of modern
combination antiretroviral therapy
E Sezgin ,1,2 ML Van Natta,2 JE Thorne,2,3 MA Puhan2,4 and DA Jabs2,5,6 for the Longitudinal Studies of the Ocular
Complications of AIDS (SOCA) Research Group
1Laboratory of Nutrigenomics and Epidemiology, Department of Food Engineering, Izmir Institute of Technology, Izmir,
Turkey, 2Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD,
USA, 3Department of Ophthalmology, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine,
Baltimore, MD, USA, 4Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland,
5Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA and 6Department of
Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Objectives
The aim of the study was to estimate the incidence of, determine risk factors for, and investigate
the consequences of opportunistic infections (OIs) and malignancies among patients with the
acquired immune deficiency syndrome (AIDS) in the era of modern combination antiretroviral
therapy (cART).
Methods
Three enrolment periods (1998–2002, 2003–2005 and 2006–2012), corresponding to changes in
predominant cART regimens, were compared among 1889 participants enrolled in a prospective
cohort study, the Longitudinal Study of Ocular Complications of AIDS (LSOCA). Incidences of
AIDS-related OIs and cancers were estimated. Multivariate logistic and Cox regression models were
used to determine the effect of demographic and clinical characteristics on OIs and mortality.
Results
Between participants enrolled in the 1998–2002 and 2006–2012 enrolment periods, the incidence
of OIs decreased from 27 per 1000 person-years (PY) to 11 per 1000 PY (P < 0.001), and mortality
decreased from 41 per 1000 PY to 18 per 1000 PY (P < 0.0001), corresponding to improvements in
cART regimens.
Conclusions
Improvements in cART regimens led to a progressive decline in the incidence of OIs and mortality
between 1999 and 2013 among patients with AIDS in the era of modern cART.
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Introduction
With the advent of modern combination antiretroviral
therapy (cART) in the mid-1990s, the incidences of HIV-
associated opportunistic infections (OIs), cancers, and
mortality have decreased substantially [1–15]. Despite the
decline in HIV-associated OIs and cancers over the last
two decades, their incidences never reached those of peo-
ple without HIV infection, and they remain a leading
cause of mortality and morbidity [9,16–25].
Because recommendations for cART are to start it at
CD4 T-cell levels well above those at which the acquired
immunodeficiency syndrome (AIDS) would be diagnosed
and prior those increasing the risk for OIs, most studies
demonstrating the benefits of cART on OIs involve
cohorts of patients including patients with earlier stages
of HIV infection. Among those at risk for OIs,
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prophylactic antimicrobial therapy [such as against Pneu-
mocystis jirovicii pneumonia (PJP) and Mycobacterium
avium complex (MAC)] also have been effective in
decreasing the incidence of OIs [5,7,8]. In the modern
cART era, OIs still occur, albeit at a substantially reduced
rate, and are associated with lower CD4 T-cell counts and
higher amounts of circulating HIV RNA in the blood (HIV
load) [20,26,27]. Because most of the studies demonstrat-
ing the beneficial effect of cART on the incidence of OIs
come from cohorts with earlier stages of HIV infection,
there are few data on secular trends in the incidence of
OIs among patients with the late stage of HIV infection,
namely AIDS [28–31]. However, AIDS continues to occur,
largely because of late diagnosis of HIV infection, but
also because of failure in some patients to suppress HIV
replication with cART [15,32–34].
The Longitudinal Study of the Ocular Complications of
AIDS (LSOCA) is a 15-year prospective cohort study con-
ducted in the era of modern cART, and is unique in that it
only enrolls patients with AIDS, and with a wide range of
immune function, from diverse HIV risk groups. As such, it
provides a unique opportunity to evaluate the effect of
cART and changes in cART regimens on the incidence of
AIDS-related OIs, cancers and mortality among patients
with late-stage HIV infection, namely AIDS.
Patients and methods
LSOCA is a prospective observational study of patients
with AIDS conducted in the era of modern cART [35,36].
Patients aged ≥ 13 years with a diagnosis of AIDS accord-
ing to the 1993 definition of the Centers for Disease Con-
trol and Prevention (CDC) case surveillance were enrolled
between 1 September 1998 and 31 December 2011 at 19
centres across the USA. Only patients without an ocular OI
(namely cytomegalovirus (CMV) retinitis) are included in
this analysis to avoid enrolment bias. After the initial
recruitment period, rolling recruitment was used to provide
ongoing information on changes in the AIDS epidemic.
Demographic information and a detailed medical history,
including all OIs and current and previous ART, were
obtained at enrolment and confirmed by record review as
appropriate. A limited medical and a complete ophthalmic
examination were performed [35,37]. Enrolment laboratory
testing included a complete blood count, serum chemis-
tries, and measurements of CD4 T-cell counts and HIV
loads. The diagnosis of OIs was made according to the
AIDS Clinical Trials Group guidelines [31], and information
was collected on OIs and AIDS-related cancers; and for the
purposes of this analysis, OIs and cancers were those con-
sidered AIDS-defining based on the CDC revised 1993
AIDS case surveillance definition and the 5 December 2008
CDC OI reporting guidelines (http://www.cdc.gov/mmwr/
preview/mmwrhtml/rr5710a2.htm) [38,39]. Participants
were seen every 6 months in follow-up. The study and the
protocol were approved by institutional review boards at
all participating centres; enrolled participants provided
written informed consent; and the study and procedures
adhered to the Declarations of Helsinki.
Combination ART was defined as any of the following:
treatment with any three antiretrovirals, one of which was
either a protease inhibitor, a nonnucleoside reverse tran-
scriptase inhibitor (NNRTI) or a fusion, integrase or entry
inhibitor; any three nucleoside reverse transcriptase inhibi-
tors, one of which was abacavir or tenofovir (except for the
regimens abacavir/tenofovir/lamivudine and didanosine/
tenofovir /lamivudine); two full-dose protease inhibitors; a
boosted protease inhibitor with either an NNRTI or a fusion
inhibitor; or an integrase inhibitor combined with either a
protease inhibitor, NNRTI, entry inhibitor or fusion inhibitor.
If zidovudine and stavudine were present in the same regi-
men, they were removed from that regimen’s total antiretro-
viral count because of their known antagonism [28].
In order to assess secular changes in the incidence of
OIs and malignancies, participants were grouped into
three recruitment periods: 1998–2002; 2003–2005 and
2006–2012. These enrolment periods were selected to
coincide with changes in the predominant cART regimen
being used (Table S1). Because of the initial bolus of
recruitment, the initial recruitment period contained
slightly over 60% of the participants.
Patient data collected and reported to the Coordinating
Center as of 31 December 2012 were included in the analy-
ses. Mortality analysed throughout the study represents
all-cause mortality. Follow-up time was calculated as the
time from study entry to first incidence, to death, or to 31
December 2012 for patients under active follow-up, or to
the date of the last study contact for patients who were lost
to follow-up. Mortality and incidence rates were calculated
as the number of deaths and number of AIDS-defining
conditions divided by the number of person-years at risk.
Relative risks were estimated with Cox proportional haz-
ards. Survival analyses were performed with staggered
entries based on time since diagnosis of AIDS. Analyses
were performed with the SAS/STAT version 9.3 (SAS Insti-
tute, Inc., Cary, NC, USA) and STATA version 12.0 (StataCorp
LP, College Station, TX, USA) software packages.
Results
Characteristics of the study population
Enrolment characteristics of the three enrolment cohorts
of LSOCA are shown in Table 1. Of the 1889 participants,
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1180 were enrolled in the first cohort, 329 in the second,
and 380 in the third. Consistent with changes in the AIDS
epidemic, there was a decrease in the proportion of par-
ticipants who were white and whose HIV transmission
category was male-to-male sexual contact after the first
enrolment period. There was also an increase in the pro-
portion of participants whose AIDS-defining condition
was CD4 T-cell lymphopaenia, as opposed to an OI, in
the third recruitment period vs. the first and second
recruitment periods (74% vs. 64% and 62%, respectively;
P < 0.001). Participants in the third recruitment period
had higher enrolment CD4 T-cell counts than those in the
first two recruit periods (median 282 vs. 174 and
197 cells/lL, respectively; P < 0.0001) and lower HIV
loads (median 2.0 vs. 3.3 and 2.6 log10 HIV RNA copies/
mL, respectively; P < 0.0001). Although there was an
apparent increase in cART use prior to enrolment with
each successive recruitment period (76% vs. 83% vs.
94%, respectively; P < 0.0001), there was no significant
difference in the use of cART during follow-up among
the three groups, and overall 97% of participants received
cART during follow-up.
Incidence of opportunistic infections and
AIDS-associated malignancies
There were 135 incident OI events during 13 689 person-
years (PY) of observation (20 per 1000 PY). The incidence
Table 1 Patient characteristics at enrolment in the Longitudinal Study of the Ocular Complications of AIDS cohort
Characteristic
Enrolment cohort
Total (n = 1889) P-value*1998–2002 (n = 1180) 2003–2005 (n = 329) 2006–2012 (n = 380)
Age (years) [median (25th, 75th percentile)] 42 (37,47) 44 (40,51) 46 (40, 52) 43 (38, 49) < 0.0001
Male (%) 81 77 80 80 0.36
Race (%)
White 50 34 39 45 < 0.0001
African American 33 45 48 38
Other 17 20 13 17
HIV transmission category (%)
Male-to-male sexual contact 57 48 51 54 0.02
Injecting drug use† 12 18 16 14
Other 31 34 33 32
Any insurance (%) 82 89 84 83 0.08
Time since AIDS diagnosis (years)
[median (25th, 75th percentile)]
4.0 (1.6, 6.4) 5.5 (1.7, 8.7) 4.7 (1.1, 8.2) 4.3 (1.6, 7.2) < 0.0001
AIDS diagnosis category (%)
CD4 T-cell lymphopaenia 64 62 74 65 < 0.001
Opportunistic infection or malignancy 32 34 23 31
Enrolment CD4 T-cell count (cells/lL)
Median (25th, 75th percentile) 174 (66,325) 197 (104,380) 282 (124,427) 197 (80,358) < 0.0001
Per cent of participants < 200 55 50 37 51 < 0.0001
Per cent of participants 200–500 34 35 44 36
Per cent of participants > 500 11 14 19 13
Nadir CD4 T-cell count (cells/lL)
Median (25th, 75th percentile) 43 (13,112) 44 (14,101) 50 (16,133) 44 (14,115) 0.29
Per cent of participants < 50 53 53 50 53 0.24
Per cent of participants ≥ 50 47 47 40 47
Enrolment HIV load (log10 copies/mL)
Median (25th, 75th percentile) 3.3 (2.4, 4.8) 2.6 (1.9, 4.4) 2.0 (1.7, 2.7) 2.7 (1.9, 4.6) < 0.0001
Per cent of participants < 2.6 27 42 63 37 < 0.0001
Per cent of participants 2.6–5 32 29 20 29
Per cent of participants ≥ 5 40 29 17 33
Maximum prior HIV load (log10 copies/mL)
Median (25th, 75th percentile) 5.3 (4.7, 5.7) 5.3 (4.7, 5.8) 5.3 (4.8, 5.7) 5.3 (4.7, 5.7) 0.63
Per of cent participants < 5 11 11 10 11 0.38
Per cent of participants ≥ 5 89 89 90 90
ART (%)
Any ART prior to enrolment 76 83 94 81 < 0.0001
Receiving cART at enrolment 82 88 92 85 < 0.0001
Any cART during follow-up 96 96 97 97 0.14
ART, antiretroviral therapy; cART, combination antiretroviral therapy (see Methods).
*P-values comparing three cohorts.
†The injecting drug use category includes persons with any injecting drug use.
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of specific OIs by enrolment cohort is shown in Table S2
and was lower for participants enrolled in the third enrol-
ment period than for those in the first two (11 per 1000
PY vs. 27 and 23 per 1000 PY, respectively; P < 0.001).
When analysed by calendar year, the incidence of total
OIs decreased from 1999 to 2013 (P < 0.0001) but never
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Fig. 1 Incidence of (a) total and (b) selected most common AIDS-defining opportunistic infections by calendar year. CI, confidence interval.
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reached zero (Fig. 1a). The incidences of the four most
common OIs (Fig. 1b) decreased from 1999 to 2007
(P < 0.001) and then remained constant until 2013 with-
out reaching zero.
There were 45 incident AIDS-associated malignancies
during 13 689 PY of follow-up (incidence 3.7 per 1000
PY). The cancer incidence rate decreased by successive
enrolment cohort (Table 2 and Table S2). Kaposi sarcoma
and lymphomas rates were similar, with a slight decline
in the last cohort, and both had similarly low rates
throughout.
Risk factors for incident OIs and AIDS-related malignan-
cies are shown in Table 2. Being in the first enrolment
cohort, black race, enrolment CD4 T cell count < 200 cells/
lL, lower nadir CD4 T-cell count prior to enrolment, higher
HIV load at enrolment, higher maximum HIV load prior to
enrolment, and not being on cART were associated
with increased risk for OIs (Table 2). Risk factors associated
with an increased incidence of AIDS-related cancers
included enrolment CD4 T-cell count < 200 cells/lL,
higher HIV load at enrolment, and not being on any ART
(Table 2).
The median (25%, 75%) CD4 T-cell count was 100 (23,
232) cells/lL at the first follow-up visit at which an
AIDS-defining illness (any OI or cancer) was reported and
29% of the OI incidences were observed among patients
with a CD4 T-cell count > 200 cells/lL. The median HIV
load was 4.0 (2.3, 5.1) log10 copies/mL at the first follow-
up visit at which an AIDS-defining illness was reported
and 14% of the OI incidences were observed among
patients with HIV loads < 400 copies/mL.
Mortality
The overall mortality during follow-up was 37 per 1000
PY. The mortality rate decreased from 2002 to 2013
(Fig. 2a; regression P < 0.0001). There was a significant
decrease in mortality in the third enrolment cohort vs.
the first two (18 per 1000 PY vs. 34 and 41 per 1000 PY,
respectively; Fig. 2b). The relative risk (RR) for mortality
comparing the first enrolment cohorts vs. the third was
0.46 (P < 0.0001). Enrolment risk factors for mortality
are shown in Table 3. In addition to enrolment cohort,
the presence of any AIDS-related malignancy at enrol-
ment (RR = 1.62; P = 0.007) was associated with and
increased mortality.
Discussion
The LSOCA cohort is unique in that it enrolled only
patients with AIDS, with a wide range of immune func-
tion, and was not HIV transmission category restricted
[35]. As such it is uniquely positioned to evaluate the
impact of cART on AIDS-related OIs, cancers and mortal-
ity among patients with late-stage HIV infection, whereas
most other cohorts evaluate these outcomes among
patients including earlier stages of HIV infection. Our
Table 2 Association of clinical characteristics at enrolment with the
incidence of AIDS-defining opportunistic infections (OIs) and can-
cers
Any OI incidence
(n = 135)
Any cancer
incidence
(n = 45)
RR* P† RR* P†
Enrolment cohort
1998–2002 Ref Ref
2003–2005 0.83 0.48 0.84 0.69
2006–2012 0.37 0.01 0.58 0.31
AIDS diagnosis category
CD4 T-cell lymphopaenia Ref Ref
Opportunistic infection or malignancy 0.85 0.48 1.36 0.37
Race
White Ref Ref
Black 1.65 0.008 0.66 0.22
Other 0.68 0.22 0.84 0.69
Sex
Male Ref Ref
Female 1.22 0.37 0.99 0.97
Enrolment median age
≥ 43 years Ref Ref
< 43 years 1.35 0.09 0.98 0.94
HIV transmission category
Male-to-male sexual contact Ref Ref
Injecting drug use‡ 0.86 0.62 0.57 0.29
Other 1.06 0.79 0.58 0.13
Enrolment CD4 count
≥ 500 cells/lL Ref Ref
200–500 cells/lL 1.12 0.78 1.56 0.56
< 200 cells/lL 3.31 0.001 3.59 0.08
Nadir CD4 count
≥ 50 cells/lL Ref Ref
< 50 cells/lL 1.71 0.003 0.89 0.72
Enrolment HIV load
< 2.6 log10 copies/mL Ref Ref
2.6–5 log10 copies/mL 1.78 0.04 3.06 0.02
≥ 5 log10 copies/mL 4.74 < 0.0001 4.15 0.002
Maximum prior HIV load
< 5 log10 copies/mL Ref Ref
≥ 5 log10 copies/mL 2.27 0.01 2.04 0.24
Enrolment ART§
No ART Ref Ref
ART (no cART) 0.70 0.32 0.57 0.34
cART 0.37 < 0.0001 0.31 0.002
*Relative risk; Cox models with staggered entries based on time since
diagnosis of AIDS.
†Likelihood ratio v2 P-values.
‡Injecting drug use category includes persons with any injecting drug
use.
§No ART is no antiretroviral usage reported at study entry; ART (no
cART) is any antiretroviral treatment that is not considered cART; cART
is at least two different antiretrovirals in combination that qualify as
cART according to the modern classifications (see Methods for details).
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data demonstrate a secular decline in the incidence of OIs
and mortality in a cohort of patients with AIDS over the
time period 1998–2013, with the largest declines in OIs
occurring before 2007. Previous incidence studies of OIs
in HIV-infected cohorts (i.e. not restricted to AIDS at
enrolment) reported a sharp decline in the 1992–1997
period followed by a more gradual decline in 1998–2002
and low, stabilized incidences in the 2003–2007 period
[7,18,20]. Despite the improvements in OI incidence and
immune recovery, low, stabilized incidences of oppor-
tunistic illnesses are still evident in this cohort of patients
with AIDS in the 2007–2013 calendar period. The most
prevalent OIs in LSOCA were the most common OIs seen
in the pre-cART era, and they continue to be the most fre-
quently diagnosed in the modern cART era [5,6,15,40,41].
Because LSOCA enrolled only patients with AIDS, these
data uniquely address the effect of cART on late-stage
HIV infection. Indeed, the median nadir CD4 T-cell count
prior to enrolment of 44 cells/lL indicates that the
LSOCA cohort experienced profound levels of immune
compromise, and that the benefits of modern cART and
the secular trends in the modern cART era are present
even among patients with a history of severe immune
compromise. Risk factors for OIs and mortality were those
expected: lower CD4 T-cell count and higher HIV load.
Patients in the third cohort were more likely to be diag-
nosed with AIDS based on CD4 T-cell lymphopaenia rather
than based on an OI or cancer, which might in part explain
the lower mortality incidence in the third cohort. However,
AIDS diagnosis category did not have a significant effect
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on mortality, and therefore it is unlikely to have led to a
survivor bias in the last cohort. Time since AIDS diagnosis
to study enrolment was significantly different among the
cohorts. To avoid potential survival bias, we used a stag-
gered entry approach anchoring survival analysis to the
AIDS diagnosis date for each patient.
Although the LSOCA cohort enrolled only patients with
AIDS, it was not HIV transmission category restricted [35].
Previous analyses suggested that the LSOCA cohort is rela-
tively representative of the AIDS epidemic, with the excep-
tion of a slight under-representation of persons whose HIV
transmission category is injecting drug use [35]. Therefore,
LSOCA is reasonably generalizable to patients with AIDS
but not to earlier stages of HIV infection. However, because
of late diagnosis of HIV infection and difficulties control-
ling HIV replication in some patients despite good follow-
up, progression to AIDS does occur [24,32,33], so informa-
tion on late-stage HIV disease is important, and the LSOCA
results uniquely address these patients.
There are limitations to the study. As the outcome of
ocular infections (primarily CMV retinitis) was a primary
aim of LSOCA, the original cohort oversampled patients
with CMV retinitis. However, this analysis focused only on
participants without CMV retinitis, minimizing the
recruitment bias. As such, the findings should be general-
izable to the AIDS epidemic in industrialized countries.
The slight under-sampling of injecting drug users does not
appear to limit the generalizability of the study, as inject-
ing drug use was not a major risk factor for the outcomes
of interest, and there were sufficient numbers of injecting
drug users for subgroup analyses. Nevertheless, caution
should be exercised in generalizing LSOCA results.
Studies have reported improvements in HIV treatment
between 1996 and 2010, during which cART became less
toxic, with increased efficacy and higher adherence rates
leading to significant decreases in HIV RNA levels
[42,43]. Our results agree with these reports which
focused on the earlier stages of HIV infection and, more-
over, show that the efficacy of cART regimens is getting
better with time, leading to significant improvements in
patient immune health and mortality even among
patients with AIDS and a history of severe immune com-
promise.
In conclusion, this analysis of LSOCA data demonstrates
a substantial decline in per-calendar-year rates of OIs
among patients with AIDS, with the majority of the decline
occurring between 2000 and 2009. All-cause mortality per
calendar year showed a steady decline between 2002 and
2013, corresponding to a 44% overall reduction in mortal-
ity rate and a 64% reduction in mortality RR by the 2006–
2012 enrolment cohort. These results demonstrate ongoing
improvements in outcomes among patients with late-stage
HIV disease.
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Table 3 Association of cohort, AIDS diagnosis category and AIDS-
defining illnesses at enrolment with mortality
Rate*
No. deaths/
no. at risk RR† P
Overall 37 508/1889 — —
Enrolment cohort
1998–2002 41 409/1180 1.00 —
2003–2005 34 72/329 0.84 0.18
2006–2012 18 27/380 0.46 0.0001
AIDS diagnosis category
Opportunistic infection
or malignancy
40 188/654 1.06 0.60
CD4 T-cell lymphopaenia 36 320/1235 1.00 —
Opportunistic infections‡
Any opportunistic infection 39 244/862 0.99 0.98
No opportunistic infection 36 264/1027 1.00 —
Any viral infection 49 2/7 2.98 0.13
No viral infection 37 506/1882 1.00 —
Any parasitic infection 32 19/78 1.06 0.80
No parasitic infection 37 489/1811 1.00 —
Any fungal infection 39 213/746 0.99 0.96
No fungal infection 36 295/1143 1.00 —
Any mycobacterial infection 44 50/158 1.02 0.92
No mycobacterial infection 37 458/1731 1.00 —
Any cancer‡ 44 43/133 1.62 0.007
No cancer 36 465/1756 1.00 —
RR, relative risk.
*Incidence per 1000 person-years.
†Cox models with staggered entries based on time since diagnosis of
AIDS. Models were adjusted for age, sex, race, HIV transmissin category,
nadir CD4 T-cell count, baseline CD4 T-cell count, baseline and highest
recorded HIV loads, and combination antiretroviral therapy.
‡AIDS-defining opportunistic infections and cancers.
© 2018 British HIV Association HIV Medicine (2018), 19, 411--419
Secular trends in AIDS-related diseases 417
References
1 Crum-Cianflone NF, Hullsiek KH, Marconi V et al. Trends in
the incidence of cancers among HIV-infected persons and the
impact of antiretroviral therapy: authors’ reply. AIDS 2009;
23: 1791–1792.
2 Detels R, Tarwater P, Phair JP et al. Effectiveness of potent
antiretroviral therapies on the incidence of opportunistic
infections before and after AIDS diagnosis. AIDS 2001; 15:
347–355.
3 Gona P, Van Dyke RB, Williams PL et al. Incidence of
opportunistic and other infections in HIV-infected
children in the HAART era. J Am Med Assoc 2006; 296:
292–300.
4 Hessol NA, Kalinowski A, Benning L et al. Mortality among
participants in the Multicenter AIDS Cohort Study and the
Women’s Interagency HIV Study. Clin Infect Dis 2007;
44: 287–294.
5 Jones JL, Hanson DL, Dworkin MS et al. Surveillance for
AIDS-defining opportunistic illnesses, 1992–1997. Morb
Mortal Wkly Rep Surveill Summ 1999; 48: 1–22.
6 Jones JL, Hanson DL, Dworkin MS, Ward JW, Jaffe HW.
Effect of antiretroviral therapy on recent trends in selected
cancers among HIV-infected persons. Adult/Adolescent
Spectrum of HIV Disease Project Group. J Acquir Immune
Defic Syndr 1999; 21 (Suppl 1): S11–S17.
7 Kaplan JE, Hanson D, Dworkin MS et al. Epidemiology of human
immunodeficiency virus-associated opportunistic infections in the
United States in the era of highly active antiretroviral therapy.
Clin Infect Dis 2000; 30 (Suppl 1): S5–S14.
8 McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward
JW. Effects of antiretroviral therapy and opportunistic illness
primary chemoprophylaxis on survival after AIDS diagnosis.
Adult/Adolescent Spectrum of Disease Group. AIDS 1999;
13: 1687–1695.
9 Palella FJ Jr, Baker RK, Moorman AC et al. Mortality in the
highly active antiretroviral therapy era: changing causes of
death and disease in the HIV outpatient study. J Acquir
Immune Defic Syndr 2006; 43: 27–34.
10 Ledergerber B, Egger M, Erard V et al. AIDS-related
opportunistic illnesses occurring after initiation of potent
antiretroviral therapy: the Swiss HIV Cohort Study. J Am
Med Assoc 1999; 282: 2220–2226.
11 Long JL, Engels EA, Moore RD, Gebo KA. Incidence and
outcomes of malignancy in the HAART era in an urban
cohort of HIV-infected individuals. AIDS 2008; 22:
489–496.
12 Moore RD, Chaisson RE. Natural history of HIV infection in
the era of combination antiretroviral therapy. AIDS 1999;
13: 1933–1942.
13 Murphy EL, Collier AC, Kalish LA et al. Highly active
antiretroviral therapy decreases mortality and morbidity in
patients with advanced HIV disease. Ann Intern Med 2001;
135: 17–26.
14 Nesheim SR, Kapogiannis BG, Soe MM et al. Trends in
opportunistic infections in the pre- and post-highly active
antiretroviral therapy eras among HIV-infected children in
the Perinatal AIDS Collaborative Transmission Study, 1986–
2004. Pediatrics 2007; 120: 100–109.
15 Podlekareva D, Mocroft A, Dragsted UB et al. Factors
associated with the development of opportunistic infections
in HIV-1-infected adults with high CD4+ cell counts: a
EuroSIDA study. J Infect Dis 2006; 194: 633–641.
16 Bonnet F, Chene G, Thiebaut R et al. Trends and
determinants of severe morbidity in HIV-infected patients:
the ANRS CO3 Aquitaine Cohort, 2000–2004. HIV Med 2007;
8: 547–554.
17 Bonnet F, Lewden C, May T et al. Opportunistic infections as
causes of death in HIV-infected patients in the HAART era in
France. Scand J Infect Dis 2005; 37: 482–487.
18 Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur
H. HIV-associated opportunistic infections-going, going, but
not gone: the continued need for prevention and treatment
guidelines. Clin Infect Dis 2009; 48: 609–611.
19 Buchacz K, Baker RK, Moorman AC et al. Rates of
hospitalizations and associated diagnoses in a large multisite
cohort of HIV patients in the United States, 1994–2005.
AIDS 2008; 22: 1345–1354.
20 Buchacz K, Baker RK, Palella FJ Jr et al. AIDS-defining
opportunistic illnesses in US patients, 1994–2007: a cohort
study. AIDS 2010; 24: 1549–1559.
21 Gebo KA, Fleishman JA, Moore RD. Hospitalizations for
metabolic conditions, opportunistic infections, and injection
drug use among HIV patients: trends between 1996 and 2000
in 12 states. J Acquir Immune Defic Syndr 2005; 40: 609–616.
22 Hooshyar D, Hanson DL, Wolfe M, Selik RM, Buskin SE,
McNaghten AD. Trends in perimortal conditions and
mortality rates among HIV-infected patients. AIDS 2007; 21:
2093–2100.
23 Lewden C, May T, Rosenthal E et al. Changes in causes of
death among adults infected by HIV between 2000 and 2005:
the “Mortalite 2000 and 2005” surveys (ANRS EN19 and
Mortavic). J Acquir Immune Defic Syndr 2008; 48: 590–598.
24 Mocroft A, Sterne JA, Egger M et al. Variable impact on
mortality of AIDS-defining events diagnosed during
combination antiretroviral therapy: not all AIDS-defining
conditions are created equal. Clin Infect Dis 2009; 48:
1138–1151.
25 Smit C, Geskus R, Walker S et al. Effective therapy has
altered the spectrum of cause-specific mortality following
HIV seroconversion. AIDS 2006; 20: 741–749.
26 Maurer T, Ponte M, Leslie K. HIV-associated Kaposi’s
sarcoma with a high CD4 count and a low viral load. N Engl
J Med 2007; 357: 1352–1353.
© 2018 British HIV Association HIV Medicine (2018), 19, 411--419
418 E Sezgin et al.
27 Mocroft A, Kirk O, Clumeck N et al. The changing pattern of
Kaposi sarcoma in patients with HIV, 1994–2003: the
EuroSIDA Study. Cancer 2004; 100: 2644–2654.
28 Palella FJ, Baker RK, Buchacz K et al. Increased mortality
among publicly insured participants in the HIV Outpatient
Study despite HAART treatment. AIDS 2011; 25: 1865–1876.
29 Puhan MA, Van Natta ML, Palella FJ, Addessi A, Meinert C,
Ocular Complications of ARG. Excess mortality in patients
with AIDS in the era of highly active antiretroviral therapy:
temporal changes and risk factors. Clin Infect Dis 2010; 51:
947–956.
30 Simmons RD, Ciancio BC, Kall MM, Rice BD, Delpech VC.
Ten-year mortality trends among persons diagnosed with
HIV infection in England and Wales in the era of
antiretroviral therapy: AIDS remains a silent killer. HIV Med
2013; 14: 596–604.
31 Jabs DA, Holbrook JT, Van Natta ML et al. Risk factors for
mortality in patients with AIDS in the era of highly active
antiretroviral therapy. Ophthalmology 2005; 112: 771–779.
32 Finzi D, Blankson J, Siliciano JD et al. Latent infection of
CD4+ T cells provides a mechanism for lifelong persistence
of HIV-1, even in patients on effective combination therapy.
Nat Med 1999; 5: 512–517.
33 Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis
and determinants of progression to AIDS or death after HIV
diagnosis among injection drug users, 33 US States, 1996–
2004. PLoS ONE 2009; 4: e4445.
34 Schwarcz S, Hsu L, Dilley JW, Loeb L, Nelson K, Boyd S.
Late diagnosis of HIV infection: trends, prevalence, and
characteristics of persons whose HIV diagnosis occurred
within 12 months of developing AIDS. J Acquir Immune
Defic Syndr 2006; 43: 491–494.
35 Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert
CL, Davis MD. Longitudinal study of the ocular
complications of AIDS – 1. Ocular diagnoses at enrollment.
Ophthalmology 2007; 114: 780–786.
36 Jabs DA, van Natta ML, Kempen JH et al. Characteristics of
patients with cytomegalovirus retinitis in the era of highly
active antiretroviral therapy. Am J Ophthalmol 2002; 133:
48–61.
37 Jabs DA, Van Natta ML, Holbrook JT et al. Longitudinal
study of the ocular complications of AIDS: 2. Ocular
examination results at enrollment. Ophthalmology 2007; 114:
787–793.
38 Kaplan JE, Benson C, Holmes KK et al. Guidelines for
prevention and treatment of opportunistic infections in HIV-
infected adults and adolescents: recommendations from CDC,
the National Institutes of Health, and the HIV Medicine
Association of the Infectious Diseases Society of America.
Morb Mortal Wkly Rep 2009; 58: 1–207.
39 Centers for Disease Control and Prevention. 1993 revised
classification system for HIV infection and expanded
surveillance case definition for AIDS among adolescents and
adults. Morb Mortal Wkly Rep 1992; 41: 1–19.
40 Crum-Cianflone N, Hullsiek KH, Marconi V et al. Trends in
the incidence of cancers among HIV-infected persons and the
impact of antiretroviral therapy: a 20-year cohort study.
AIDS 2009; 23: 41–50.
41 Mocroft A, Katlama C, Johnson AM et al. AIDS across
Europe, 1994–98: the EuroSIDA study. Lancet 2000; 356:
291–296.
42 Moore RD, Bartlett JG. Dramatic decline in the HIV-1 RNA
level over calendar time in a large urban HIV practice. Clin
Infect Dis 2011; 53: 600–604.
43 Sax PE. Antiretroviral therapy: now “it just works”. Clin
Infect Dis 2011; 53: 605–608.
Supporting Information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Table S1. Three most frequent cART regimens (3+ ARVs)
by year of visit (as of 31Dec 2013) in the LSOCA cohort.
Table S2. Incidence of AIDS defining illnesses by enroll-
ment cohort.
Notes S1. LSOCA Clinical Centers - Credit Roster Key Per-
sonnel (LSOCA certified) 1997 - 2009
© 2018 British HIV Association HIV Medicine (2018), 19, 411--419
Secular trends in AIDS-related diseases 419
